*ST长药：股价异常波动，面临多项退市风险

Core Viewpoint - The company *ST Changyao announced a significant stock price drop of 30.25% over two consecutive trading days, indicating abnormal volatility in its stock performance [1] Financial Performance - The company reported inflated revenues of 215 million, 284 million, and 234 million from 2021 to 2023 respectively [1] - For 2024, the company projects revenue of 112 million with a net loss of 628 million [1] Risks and Compliance Issues - The company faces multiple delisting risks, including trading-related, major legal violations, and financial-related mandatory delisting risks [1] - There are ongoing legal disputes, overdue interest-bearing debts, frozen accounts, and tax arrears from its controlling subsidiary [1]